RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

Published on May 8, 2026
ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, on Wednesday announced financial results for the quarter ended March 31, 2026. In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5 percent compared with the same period in 2025, which RxSight said is largely reflective of lower light delivery device (LDD) unit volumes, consistent with expectations. Light adjustable lens (LAL) procedures decreased 0.4 percent year over year, the company advised.
Continue reading on website
Other news

The Vision Council Testifies at USTR Hearings, Urges Exclusion of Eyewear and Optical Products From Possible Tariff Actions

May 8, 2026
ALEXANDRIA, Va.—The Vision Council announced this week that Omar Elkhatib, director of government relations, testified on behalf of the group and its members on May 5 at a public hearing held at the U.S. International Trade Commission in Washington, D.C., as part of a multi-day review of whether structural excess capacity in manufacturing abroad is harming U.S. production. During his testimony, he

Safilo Group Points to Resilient Trends and Strong Margin Improvements in Q1 2026

May 8, 2026
PADUA, Italy—The board of directors of Safilo Group S.p.A. has reviewed and approved key performance indicators for the first quarter of 2026, the company announced yesterday. In the first quarter of 2026, Safilo recorded net sales of €272.9 million, up 0.4 percent at constant exchange rates. At current exchange rates, net sales declined by 4.5 percent, which the group said mainly reflects the dep